Related Experiment Video
Updated: Jan 23, 2026
Single-Port Robotic-assisted Transaxillary Breast-conserving Surgery: A Prospective, Single-arm, Non-randomized Phase IIa Clinical Trial
Published on: August 19, 2025
Robot-assisted approach to cervical cancer (RACC): an international multi-center, open-label randomized controlled
Henrik Falconer1, Kolbrun Palsdottir2, Karin Stalberg3
1Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden henrik.falconer@sll.se.
Background:
Radical hysterectomy with pelvic lymphadenectomy represents the standard treatment for early-stage cervical cancer. Results from a recent randomized controlled trial demonstrate that minimally invasive surgery is inferior to laparotomy with regards to disease-free and overall survival.
Primary Objective:
To investigate the oncologic safety of robot-assisted surgery for early-stage cervical cancer as compared with standard laparotomy.
Study Hypothesis:
Robot-assisted laparoscopic radical hysterectomy is non-inferior to laparotomy in regards to recurrence-free survival with the advantage of fewer post-operative complications and superior patient-reported outcomes.
Trial Design:
Prospective, multi-institutional, international, open-label randomized clinical trial. Consecutive women with early-stage cervical cancer will be assessed for eligibility and subsequently randomized 1:1 to either robot-assisted laparoscopic surgery or laparotomy. Institutional review board approval will be required from all participating institutions. The trial is coordinated from Karolinska University Hospital, Sweden.
Major Inclusion/Exclusion Criteria:
Women over 18 with cervical cancer FIGO (2018) stages IB1, IB2, and IIA1 squamous, adenocarcinoma, or adenosquamous will be included. Women are not eligible if they have evidence of metastatic disease, serious co-morbidity, or a secondary invasive neoplasm in the past 5 years.
Primary Endpoint:
Recurrence-free survival at 5 years between women who underwent robot-assisted laparoscopic surgery versus laparotomy for early-stage cervical cancer.
Sample Size:
The clinical non-inferiority margin in this study is defined as a 5-year recurrence-free survival not worsened by >7.5%. With an expected recurrence-free survival of 85%, the study needs to observe 127 events with a one-sided level of significance (α) of 5% and a power (1-β) of 80%. With 5 years of recruitment and 3 years of follow-up, the necessary number of events will be reached if the study can recruit a total of 768 patients.
Estimated Dates For Completing Accrual And Presenting Results:
Trial launch is estimated to be May 2019 and the trial is estimated to close in May 2027 with presentation of data shortly thereafter.
Trial Registration:
The trial is registered at ClinicalTrials.gov (NCT03719547).
Related Concept Videos
01:25Internal Forces and Center of Gravity
Internal forces are generated within a body due to the interaction between its particles. These forces can be categorized into tension, compression, and...
01:21Brainstem: Control Centers of Medulla
Olivary Nucleus
The olivary nucleus, or inferior olivary nucleus, is located within the ventrolateral part of the medulla oblongata. It is primarily involved in motor coordination and motor learning. The olivary nucleus receives input from the spinal cord, cerebellum, and motor...
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
02:00Internal Energy
02:33Lattice Centering and Coordination Number
Types of Unit Cells
Imagine taking a large number of identical...
01:31Internal Receptors